Angeles Wealth Management LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Angeles Wealth Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 18.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,679 shares of the biopharmaceutical company’s stock after buying an additional 2,882 shares during the period. Angeles Wealth Management LLC’s holdings in Pfizer were worth $496,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. V2 Financial group LLC grew its position in Pfizer by 20.6% during the fourth quarter. V2 Financial group LLC now owns 29,671 shares of the biopharmaceutical company’s stock valued at $787,000 after acquiring an additional 5,071 shares during the period. Wilsey Asset Management Inc. lifted its stake in shares of Pfizer by 7.0% in the 4th quarter. Wilsey Asset Management Inc. now owns 883,357 shares of the biopharmaceutical company’s stock valued at $23,435,000 after purchasing an additional 57,572 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth about $395,000. Kestra Private Wealth Services LLC increased its position in Pfizer by 2.8% during the 4th quarter. Kestra Private Wealth Services LLC now owns 296,263 shares of the biopharmaceutical company’s stock worth $7,860,000 after purchasing an additional 8,069 shares in the last quarter. Finally, Howland Capital Management LLC raised its holdings in Pfizer by 5.3% in the fourth quarter. Howland Capital Management LLC now owns 62,501 shares of the biopharmaceutical company’s stock valued at $1,658,000 after buying an additional 3,164 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $25.76 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $145.96 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company’s 50-day simple moving average is $26.28 and its 200-day simple moving average is $27.73.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.68%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.